Providing advanced analytical assays for new vaccines and modern cell and gene therapy products can be challenging considering the constant changes in technologies and regulatory requirements. IDT offers an in-depth characterization and release of biological materials with broad range of old and new assays for safety testing.
We will present the analytical methods used in vaccine safety testing and how they can be improved using modern technology to provide an even clearer picture of the manufacturing process and the final product.
In the molecular biology, milestones include the decoding of the genetic code, Sanger-sequencing and the PCR technology characterize the last century. The introduction of next generation sequencing or massive parallel sequencing provided new opportunities in characterization and testing of biological samples.
We will focus on adventitious virus testing (AVT) with a recent implementation of next generation sequencing (NGS). IDT recently validated an NGS-driven AVT assay, which outcompetes previous methods of virus detection like in vivo and in vitro test methods in a broad of detection and sensitivity.
Our validated NGS-based AVT assay and established follow up experiments were proven to detect adventitious viruses in the tested samples. Join our webinar to learn more about this state of the art method its advantages, key steps and possible outcomes.
Key Learning Objectives
- Understand how modern technology improves vaccine safety testing.
- Explore innovative methods for detecting adventitious viruses.
- Gain insights how to troubleshoot common issues in biological testing.
- Understand how we validated a new an NGS-driven AVT assay.
